指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

急性病患者β-内酰胺类抗生素剂量个体化共识指南:由美国临床药学院、欧洲临床微生物学与感染病学会、欧洲临床微生物学与感染病学会抗感染药物PK/PD研究组、美国感染病学会、国际治疗药物监测与临床毒理学协会、重症医学会及感染病药师学会共同认可

Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti-Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic
指南 / 共识 · Pharmacotherapy · 2026-01-01
一句话结论国际多学科专家组基于GRADE方法制定共识,推荐对急性病患者开展β-内酰胺类抗生素剂量个体化,即根据患者实测浓度调整给药方案。

β-内酰胺类抗生素是急性病患者多数主要感染综合征的一线治疗,体外活性好、试验证实有效且不良事件风险 perceived 低。现行基于群体数据的给药方法常简化为仅按体重(儿科)和终末器官功能估算药物清除率的「一刀切」方案,导致急性病患者 observed 血药浓度变异大,可能影响真实世界疗效与安全性。β-内酰胺剂量个体化(根据患者实测浓度制定给药方案)已被国际临床指南推荐,但缺乏全面实施指导。为此,来自感染病学、重症医学、定量药理学和实验室医学的多学科国际专家组系统评价文献,在可行处采用GRADE方法,围绕是否应开展剂量个体化、哪些适应症需要个体化以及实施的关键考虑与最佳实践等主题提出共识建议。

要点

  • β-内酰胺剂量个体化定义为根据患者实测浓度制定给药方案,国际临床指南已推荐该做法。
  • 现行仅按体重(儿科)和终末器官功能估算清除率的「一刀切」给药导致急性病患者血药浓度变异大,可能影响疗效与安全性。
  • 多学科国际专家组系统评价文献,在可行处采用GRADE方法,针对是否应个体化、哪些适应症需要个体化及实施最佳实践提出共识建议。
  • 共识建议旨在为治疗急性病患者的医务人员提供证据与工具,以指导β-内酰胺剂量个体化的优化使用。

适用人群与场景

  • 急性病患者,包括成人及儿科,接受β-内酰胺类抗生素治疗者。

研究设计与关键结果

  • 制定机构:由美国临床药学院、欧洲临床微生物学与感染病学会、欧洲临床微生物学与感染病学会抗感染药物PK/PD研究组、美国感染病学会、国际治疗药物监测与临床毒理学协会、重症医学会及感染病药师学会共同认可。
  • 方法:多学科国际专家组(感染病学、重症医学、定量药理学、实验室医学,涵盖成人及儿科)系统评价文献,在可行处采用GRADE方法。
  • 主题:是否应开展β-内酰胺剂量个体化、哪些适应症需要个体化、实施的关键考虑与最佳实践。

证据类型、等级与局限

  • 证据类型:国际多学科专家共识指南,采用GRADE方法(可行处)系统评价文献。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,共识建议可为治疗急性病患者的医务人员提供证据与工具,以指导β-内酰胺剂量个体化的优化使用。

指南或共识出处

  • 共识指南标题:Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients;发布机构:美国临床药学院、欧洲临床微生物学与感染病学会、欧洲临床微生物学与感染病学会抗感染药物PK/PD研究组、美国感染病学会、国际治疗药物监测与临床毒理学协会、重症医学会、感染病药师学会。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Beta-lactam antibiotics (beta-lactams) are first-line treatments for most major infectious syndromes in acutely ill patients, with in vitro activity against common pathogens, demonstrated efficacy in trials, and a perceived low risk of adverse effects. The current dosing approach, informed by population-level data, tends to be simplistically reduced to a "one size fits all" dosing method which only accounts for body weight (i.e., in pediatrics) and end organ function to estimate drug clearance (e.g., estimated glomerular filtration rate); this approach results in substantial variability in observed serum concentrations in acutely ill patients, which can compromise real-world effectiveness and safety. Beta-lactam dose individualization, therefore, defined as a dosing regimen for one patient informed by measured concentrations from that patient, has been recommended in international clinical guidelines. Comprehensive guidance on best practices for beta-lactam dose individualization is lacking. To address this knowledge gap and develop guidance, a multidisciplinary panel of international experts was assembled from the disciplines of infectious diseases, critical care, pharmacometrics, and laboratory medicine, representing both adults and pediatrics. The panel systematically evaluated the literature, using the GRADE approach where feasible, to address broad thematic questions pertaining to whether beta-lactam dose individualization should be pursued, for what indications beta-lactam dose individualization is warranted, and the most critical considerations and best practices for implementation of beta-lactam individualization. The resultant consensus recommendations will equip healthcare professionals caring for acutely ill patients treated with beta-lactam therapy with the evidence and tools necessary to guide optimal use of beta-lactam dose individualization.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

参考来源

  1. Barreto EF, McCreary EK, Pai Mangalore R, et al. Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti-Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2026. PMID: 42487243. doi:10.1002/phar.70181

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。